Regardless of whether your group has been diligently planning for scale-up since Phase I or you have delayed scale-up work until now, it would be a mistake to assume Phase III will be clear sailing. The reality is that several manufacturability problems could be brewing that will rain down during Phase III and cause costly delays, no matter how skilled the product and process development teams may be. This white paper takes a look at some factors that pharmaceutical companies of all sizes and experience levels must consider to ensure their formulations are successful during larger-scale manufacturing.
Please check the highlighted fields and try again.
Please fill out the information below. If you are already registered, login and this information will be filled out for you.
Please enter your first and last name.
Please enter the name of the company or institution you work at.
Please enter your mailing address.
Please enter the e-mail address you would like to be contacted at.
Please enter the phone number you would like to be contacted at.